KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Operating Leases (2022 - 2024)

Historic Operating Leases for Regeneron Pharmaceuticals (REGN) over the last 4 years, with Q4 2025 value amounting to $986.8 million.

  • Regeneron Pharmaceuticals' Operating Leases rose 339.48% to $986.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $986.8 million, marking a year-over-year increase of 339.48%. This contributed to the annual value of $986.8 million for FY2025, which is 339.48% up from last year.
  • Regeneron Pharmaceuticals' Operating Leases amounted to $986.8 million in Q4 2025, which was up 339.48% from $954.4 million recorded in Q4 2024.
  • Regeneron Pharmaceuticals' 5-year Operating Leases high stood at $986.8 million for Q4 2025, and its period low was $788.2 million during Q4 2022.
  • Over the past 4 years, Regeneron Pharmaceuticals' median Operating Leases value was $881.0 million (recorded in 2023), while the average stood at $884.3 million.
  • In the last 5 years, Regeneron Pharmaceuticals' Operating Leases skyrocketed by 247.4% in 2023 and then soared by 1816.27% in 2024.
  • Over the past 4 years, Regeneron Pharmaceuticals' Operating Leases (Quarter) stood at $788.2 million in 2022, then grew by 2.47% to $807.7 million in 2023, then rose by 18.16% to $954.4 million in 2024, then grew by 3.39% to $986.8 million in 2025.
  • Its Operating Leases stands at $986.8 million for Q4 2025, versus $954.4 million for Q4 2024 and $807.7 million for Q4 2023.